Amylyx Pharmaceuticals(NASDAQ) AMLX

Amylyx Pharmaceuticals, Inc. makes medicines for rare brain and hormone diseases. It helps patients with dangerous blood sugar drops after weight-loss surgery. The company also creates treatments for serious diseases affecting the nerves.

Medicines in the Making

• Avexitide: Glucagon-like peptide-1 (GLP-1) receptor antagonist for post-bariatric hypoglycemia (PBH), a condition causing rapid blood sugar drops after surgery.
• AMX0035: Combination therapy targeting cell stress in Wolfram syndrome, a rare disease that causes vision loss and diabetes.
• AMX0114: Targeted genetic tool designed to treat amyotrophic lateral sclerosis (ALS), a fatal condition where muscle-controlling nerves die.
• AMX0318: Long-acting treatment candidate for rare hormone conditions being prepared for an Investigational New Drug application (IND) in 2027.

Strategic Pipeline Moves

• Initiated an Expanded Access Program (EAP) in May 2026 to provide avexitide to certain adults with PBH.
• Selected AMX0318 as a development candidate in January 2026 for the treatment of rare endocrine diseases.
• Formed a research collaboration with Gubra in July 2026 to identify new candidates for hormone disorders.
• Presented 96-week clinical data in June 2026 for AMX0035 treatment in patients with Wolfram syndrome.
• Settled the February 2024 Shih Complaint, which contributed to higher legal costs during the 2026 fiscal year.

What Makes Amylyx Unique

Amylyx focuses on rare orphan diseases where patients currently have no approved treatment options. Its research targets specific biological pathways, such as cell stress, that contribute to nerve damage and metabolic issues.

The Financial Scorecard

• Market capitalization was $2.4 billion as of the second quarter of 2026.
• Cash, cash equivalents, and marketable securities was $250.8 million as of June 30, 2026.
• Net loss was $84.7 million for the six-month period ended June 30, 2026.
• Research and development expenses were $51.4 million for the six-month period ended June 30, 2026.
• Selling, general, and administrative expenses were $38.1 million for the six-month period ended June 30, 2026.

Bottom Line

Amylyx has rebuilt its pipeline to focus on rare endocrine and neurodegenerative conditions following the discontinuation of its previous main product. Its future success depends on clinical results and potential regulatory approvals for its lead candidates like avexitide.